Source: https://www.pharmacoeconomics.ru/jour/article/view/164
Timestamp: 2019-04-20 10:28:55+00:00

Document:
DIREG 2, epidemiology, NAFLD, non-alcoholic fatty liver disease, NASH, non-alcoholic steatohepatitis, prevalence.
1. Bokeriya L. A. i dr. Byulleten’ NTsSSKh im. AN Bakuleva RAMN. 2007; 8 (5): 5-11.
2. Drapkina O. M., Korneeva O. N., Ivashkin V. T. Lechashchii vrach. 2010; 2: 43-45.
3. Drapkina O. M., Ivashkin V. T. RZhGGK. 2014; 4: 32-38.
4. Ivashkin V. T., Maevskaya M. V, Pavlov Ch. S., Shirokova E. N., Bueverov A. O., Drapkina O. M., Shul’pekova Yu. O., Tsukanov V. V., Mammaev S. N., Pal’gova L. K., Tikhonov I. N. Diagnosis and treatment of nonalcoholic fatty liver disease [Diagnostika i lechenie nealkogol’noi zhirovoi bolezni pecheni. Metodicheskie rekomendatsii dlya vrachei. ROPIP (in Russian)]. Moscow. 2015. URL: http://www.rsls.ru/files/Guidelines-RSLS-NASH- 2016-01-03.pdf. Accessed: 13.03.2016.
5. Ivashkin V. T., Maevskaya M. V. Ros zhurn gastroenterol gepatol koloproktol. 2010; 1: 4-13.
6. Ivashkin V. T. i soavt. Rossiiskie meditsinskie vesti. 2014; 4: 82-91.
7. Ivashkin V. T., Drapkina O. M., Maev I. V., Trukhmanov A. S., Blinov D. V., Pal’gova L. K., Tsukanov V. V., Ushakova T. I. RZhGGK. 2015; 6: 31-41.
8. Ignat’eva V. I., Avksent’eva M. V. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya / PHARMACOECONOMICS. Modern pharmacoeconomics and pharmacoepidemiology. 2014; 3: 3-11.
9. Korneeva O. N., Drapkina O. M. Ros. zhurn. gastroenterol., gepatol., koloproktol.. 2007; 1 (17): 65.
10. Lazebnik L. B., Zvenigorodskaya L. A. Metabolic syndrome and digestive organs [Metabolicheskii sindrom i organy pishchevareniya (in Russian)]. Moscow. 2009; 182 s.
11. Lipatova L. V. pilepsiya i paroksizmal’nye sostoyaniya / Epilepsy and paroxysmal conditions. 2010; 3: 20-27.
12. Makarov I. O., Borovkova E. I., Kazakov R. D. Akusherstvo, ginekologiya i reproduktsiya / Obstetrics, gynecology and reproduction. 2012; 4: 18-21.
13. Makarov I. O., Pavlov Ch. S., Shemanaeva T. V., Voevodin S. M., Muravei A. Yu. Akusherstvo, ginekologiya i reproduktsiya / Obstetrics, gynecology and reproduction. 2013; 1: 22-25.
14. Mamedov M. N., Oganov R. G. Profilaktika zabolevanii i ukreplenie zdorov’ya. 2005; 8 (6): 41-45.
15. Odinak M. M., Bazilevich S. N., Dyskin D. E., Prokudin M. Yu. Epilepsiya i paroksizmal’nye sostoyaniya / Epilepsy and paroxysmal conditions. 2010; 3: 45-50.
16. Polivanov V. A. FARMAKOEKONOMIKA. Sovremennaya farmako-ekonomika i farmakoepidemiologiya / PHARMACOECONOMICS. Modern pharmacoeconomics and pharmacoepidemiology. 2009; 1: 7-11.
17. Tsukanov V. V., Tonkikh Yu. L., Kasparov E. V. et al. Vrach. 2010; 9: 1-4.
18. Shul’pekova Yu. O. Farmateka. 2007; 141 (6): 48-53.
19. Aithal G. P., Das K., Chowdhury A. Epidemiology of Nonalcoholic Fatty Liver Disease (NAFLD). GI Epidemiology: Diseases and Clinical Methodology, Second Edition. 2014; 357-372.
20. Alberti K. G., Zimmet P., Shaw J.; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome – a new worldwide definition. Lancet. 2005; 366 (9491): 1059-1062.
21. Anfossi G., Massucco P., Bonomo K., Trovati M. Prescription of statins to dyslipidemic patients affected by liver diseases: a subtle balance between risks and benefits. Nutr. Metab. Cardiovasc. Dis. 2004; 14: 215-224.
22. Argo S. K., Loria P., Caldwell S. H., Lonardo A. Statins in liver disease: a molehill, an iceberg, or neither? Hepatology. 2008; 48 (2): 662-669.
23. Browning J. S., Szczepaniak L. S., Dobbings L. S., et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004; 40 (7): 1387-95.
24. Brunt E. M. Nonalcoholic steatohepatiatis. Semin Liver Dis. 2004; 24: 3-20.
25. Clark J. M. The epidemiology of nonalcoholic fatty liver disease in adults. J. Clin. Gastroenterol. 2006; 40: 5-10.
26. De Alwis N. M., Day C. P. Non-alcoholic fatty liver disease: the mist gradually clears. J Hepatol. 2008; 48 (1): 104-112.
27. de Denus S., Spinier S. A., Miller K. Statins and liver toxicity: a meta-analysis. Pharmactiherapy. 2004; 24 (5): 584-591.
28. Drapkina O., Evsyutina Y., Ivashkin V. Prevalence of non-alcoholic fatty liver disease in the Russian Federation: the open, multicenter, prospective study, DIREG 1. American Journal of Clinical Medicine Research. 2015; 3 (2): 31-36.
29. Drapkina O. M., Ivashkin V. T. Liver disease structure explored in Russian Federation: national-wide DIREG-L-01903 study for non-alcoholic fatty liver disease screening. Journal of Hepatology. 2011; 54: 332.
30. Forse R. A., Krishnamurty D. M. Epidemiology and Discrimination in Obesity. The ASMBS Textbook of Bariatric Surgery. Springer New York. 2015; 3-12.
31. Goland S. et al. Cardiac abnormalities as a new manifestation of nonalcoholic fatty liver disease: echocardiographic and tissue Doppler imaging assessment. Journal of clinical gastroenterology. 2006; 40 (10): 949-955.
32. Grundy S. M., Cleeman J. I., Daniels S. R. et al.; American Heart Association; National Heart, Lung, and Blood Institute (2005) Diagnosis and management of the metabolic syndrome: an American Heart Association / National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 112 (17): 2735-2752.
33. Gundermann K. J., Kuenker A., Kuntz E., Droździk M. Activity of essential phospholipids (EPL) from soybean in liver diseases. Pharmacol Rep. 2011; 63: 643-659.
34. Hamaguchi M., Kojima T., Takeda N. et al. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol. 2007; 13: 1579-84.
35. Haring R., Wallaschofski H., Nauck M., Dцrr M., Baumeister S. E., Vцlzke H. Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl-transpeptidase levels. Hepatology. 2009; 50: 1403-11.
36. Ivashkin V. T., Drapkina O. M., Maev I. V., Troukhmanov A. S., Zimovina U. V., Palgova L. K., Blinov D. V., Shirokova E. N., Tsukanov V. V. Non-alcoholic fatty liver disease risk factors assessment among the general practitioners and gastroenterologist’s patients flow. United European Gastroenterology Journal. 2015; 3 (1): 344-345.
37. Ivashkin V. T., Drapkina O. M., Maev I. V., Troukhmanov A. S., Zimovina U. V., Palgova L. K., Blinov D. V., Shirokova E. N., Tsukanov V. V. Non-alcoholic fatty liver disease risk factors assessment among the general practitioners and gastroenterologist’s patients flow. UEG Week 2015. UEG15-ABS-3697.
38. Lazo M., Hernaez R., Bonekamp S., et al. Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study. BMJ. 2011; 343: d6891.
39. Ludwig J., Viggiano T. R., McGill D. B., Oh B. J. Nonalcoholic steatohepati-tis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin. Proc. 1980; 55: 434-438.
40. Marchesini G., Brizi M., Bianchi G., Tomassetti S., Bugianesi E., Lenzi M., McCullough A. J., Natale S., Forlani G., Melchionda N. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes. 2001; 50: 1844-50.
41. McCullough A. J. Epidemiology of the metabolic syndrome in the USA. Journal of digestive diseases. 2011; 12 (5): 333-340.
42. Neuschwander-Tetri B. A., Caldwell S. H. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology. 2003; 37: 1202-19.
43. Nomura H., Kashiwaqi S., Hayashi J., et al. Prevalence of fatty liver in a general population of Okinawa Japan. Jap J Med. 1998; 27 (1): 142-9.
44. Picardi A., Vespasiani-Gentilucci U. Association between non-alcoholic fatty liver disease and cardiovascular disease: a first message should pass. Am J Gastroenterol. 2008; 103: 3036-8.
45. Sanyal A. J., Banas C., Sargeant C., Luketic V. A., Sterling R. K., Stravitz R. T., et al. Similarities and differences in outcomes of cirrhosis due to non-alcoholic steatohepatitis and hepatitis C. Hepatology. 2006; 43: 682-689.
46. Schwimmer J. B. et al. Prevalence of fatty liver in children and adolescents. Pediatrics. 2006; 118 (4): 1388-1393.
47. Sookoian S., Pirola C. J. Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review. Journal of hepatology. 2008; 49 (4): 600-607.
48. Targher G., Marra F., Marchesini G. Increased risk of cardiovascular disease in non- alcoholic fatty liver disease: causal effect or epiphenome-non? Diabetologia. 2008; 51: 1947-1953.

References: V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V.